Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;38(8):1541-1545.
doi: 10.1002/mds.29449. Epub 2023 May 23.

Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations

Affiliations

Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations

Julian Agin-Liebes et al. Mov Disord. 2023 Aug.

Abstract

Objective: To assess for TDP-43 deposits in brains with and without a LRRK2 G2019S mutation.

Background: LRRK2 G2019S mutations have been associated with parkinsonism and a wide range of pathological findings. There are no systematic studies examining the frequency and extent of TDP-43 deposits in neuropathological samples from LRRK2 G2019S carriers.

Methods: Twelve brains with LRRK2 G2019S mutations were available for study from the New York Brain Bank at Columbia University; 11 of them had samples available for TDP-43 immunostaining. Clinical, demographic, and pathological data are reported for 11 brains with a LRRK2 G2019S mutation and compared to 11 brains without GBA1 or LRRK2 G2019S mutations with a pathologic diagnosis of Parkinson's disease (PD) or diffuse Lewy body disease. They were frequency matched by age, gender, parkinsonism age of onset, and disease duration.

Results: TDP-43 aggregates were present in 73% (n = 8) of brains with a LRRK2 mutation and 18% (n = 2) of brains without a LRRK2 mutation (P = 0.03). In one brain with a LRRK2 mutation, TDP-43 proteinopathy was the primary neuropathological change.

Conclusions: Extranuclear TDP-43 aggregates are observed with greater frequency in LRRK2 G2019S autopsies compared to PD cases without a LRRK2 G2019S mutation. The association between LRRK2 and TDP-43 should be further explored. © 2023 International Parkinson and Movement Disorder Society.

Keywords: LRRK2; TDP-43; neuropathology.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure/Conflict of Interest concerning the research related to the manuscript: None

Figures

Figure 1 Legend:
Figure 1 Legend:
Photomicrographs of immunohistochemical stains against non-phosphorylated TDP-43. A: Arrow pointing to dystrophic neurites in amygdala of case 8. Original magnification 400X; TDP-43. B: Arrows pointing to dystrophic neurites in substantia nigra of case 1. Original magnification 400X; TDP-43. C: Arrow pointing to a long, thick dystrophic neurite in the motor cortex of case 7 with a pathologic diagnosis of FTLD type C. Original magnification 630X; TDP-43.

References

    1. Healy DG, Falchi M, O’Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol. 2008;7(7):583–90. - PMC - PubMed
    1. Schulte C, Gasser T. Genetic basis of Parkinson’s disease: inheritance, penetrance, and expression. Appl Clin Genet. 2011;4:67–80. - PMC - PubMed
    1. Lee AJ, Wang Y, Alcalay RN, Mejia-Santana H, Saunders-Pullman R, Bressman S, et al. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry. Mov Disord. 2017;32(10):1432–8. - PMC - PubMed
    1. Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, Tazir M, et al. G2019S LRRK2 mutation in French and North African families with Parkinson’s disease. Ann Neurol. 2005;58(5):784–7. - PubMed
    1. Marder K, Wang Y, Alcalay RN, Mejia-Santana H, Tang MX, Lee A, et al. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology. 2015;85(1):89–95. - PMC - PubMed

Publication types

MeSH terms

Substances